Marco Meglio, Editor for NeurologyLive, has been with the team since October 2019. Follow him on Twitter @marcomeglio1 or email him at firstname.lastname@example.org
Cleveland Clinic Names Epilepsy Specialist as Inaugural Chief Research Information Officer
Lara Jehi, MD, professor of neurology and co-director of Network Capacity for the Clinical and Translational Science Collaborative of Cleveland Clinic, has been appointed as the inaugural chief research information officer.
Gut Microbiome Serves as a Potential Pathway to Epilepsy Treatment
Daniel Lowenstein, MD, professor of neurology and executive vice chancellor and provost at the University of California, San Francisco spoke to the research on the gut microbiome and its parallels to epilepsy.
New Relapsing MS Trial Seeks to Compare Stem Cell Transplant With Biologic Drugs
The trial will determine whether autologous hematopoietic stem cell transplantation is a more appropriate treatment option for patients with severe forms of relapsing MS compared to currently available biologic drugs.
Lemborexant Superior to Zolpidem, Placebo for Insomnia Treatment
The drug was associated with significant improvements in sleep onset, sleep efficiency, and wake-after-sleep onset for both doses compared with placebo.
Revised ALS Disability Assessment Shows Promise as Clinical Trial Outcome Measure
The newly created 28-question assessment showed improved item targeting compared with the current standard Amyotrophic Lateral Sclerosis Functional Rating Scale.
Lasmiditan Effective in Migraine Regardless of Prior Triptan Use
Lasmiditan was efficacious across a number of doses in patients with migraine regardless of prior good or insufficient response to triptan administration.
Nilotinib May Hold Promise as Parkinson Disease Treatment
The results pave the way for a potential phase 3 trial to examine the effects of nilotinib in patients with Parkinson disease.
Comprehensive Migraine Initiative Improves Emergency Department Management of Pediatric Migraine
A standardized treatment protocol in emergency departments lead to significant reductions in headache pain.
Suvodirsen Clinical Trials in Duchenne Muscular Dystrophy Discontinued
Wave Life Sciences has discontinued its suvodirsen clinical trials after investigators saw no change from baseline in either of the dose groups.
Trial Will Assess Blood-Based Biomarker to Distinguish Epileptic From Psychogenic Seizures
A new trial will aim to confirm the findings of a previous study that showed novel combinations of peripherally circulating proteins coupled with risk factors can provide a diagnostic tool with significant clinical unity.
Biogen Discontinues Gosuranemab Trial in Progressive Supranuclear Palsy
Although the study did not meet primary and secondary endpoints in patients with PSP, Biogen still plans to continue to study the drug for mild cognitive impairment in Alzheimer disease.
EEG-fMRI Aids Surgical Planning in Epilepsy and May Improve Outcomes
Electroencephalography-functional magnetic resonance imaging can better identify the epileptogenic focus, resulting in a direct impact on patient management and surgery decision-making.
Post-Dose Somnolence With Intranasal Midazolam Not Common, Study Finds
Patients were more affected by seizure cluster control and need for additional midazolam dosing than post-dose somnolence.
CBD Improves Non-Seizure Outcomes in Dravet and Lennox-Gastaut Syndromes
Data suggests that treatment with cannabidiol is associated with other benefits besides a decrease in seizure frequency.
Cenobamate Safe, Effective Over Long-Term Treatment
Adjunctive cenobamate demonstrated a good tolerability and safety profile, as well as sustained efficacy, in patients with uncontrolled focal seizures.
Treatment With Fenfluramine Linked to Improved Executive Function in Dravet Syndrome
Fenfluramine oral solution is currently being evaluated by the FDA for the treatment of seizures associated with Dravet syndrome.
Seizure Freedom Persists With Intranasal Midazolam Regardless of Concomitant AEDs
Patients treated with intranasal midazolam who were on enzyme-inducing AEDs experienced numerically lower treatment-emergent adverse events.
American Epilepsy Society Honors Members for Outstanding Contributions
The American Epilepsy Society recognized several members from its clinical and research communities for their outstanding contributions to the field of epilepsy.
Diazepam Nasal Spray Demonstrates Good Safety, Tolerability Independent of Usage Frequency
An analysis of 2 different doses of intranasal diazepam showed consistent safety and tolerability results for repeat dosing
Telemedicine Benefits a Range of Neurologic Disorders
Although there are gaps in knowledge, investigators see potential in telemedicine for other neurologic disorders beyond stroke.
Ubrogepant Provides Rapid Pain, Symptom Relief for Acute Migraine
Results of the phase 3 ACHIEVE I trial showed a high percentage of patients were free from their most bothersome symptoms 2 hours post dose.
In Dementia, Pimavanserin Significantly Reduces Psychosis Relapse
The director emeritus of the Cleveland Clinic Lou Ruvo Center for Brain Health discussed the significance of the HARMONY study findings and what they mean for the future treatment of dementia-related psychosis.
Lacosamide Noninferior to Carbamazepine for Epilepsy Treatment
The drug was proven to be efficacious and generally well tolerated in adults with newly diagnosed epilepsy.
Three Antiepileptic Drugs Prove Equally Effective for Treating Status Epilepticus
Patients who were administered levetiracetam, fosphenytoin, or valproate saw similar improvements in seizure reduction and responsiveness.
Phase 3 Trial of Sovateltide for Acute Ischemic Stroke Commences
Top line results from the phase 3 trial of sovateltide in patients with acute cerebral ischemic stroke are expected by mid-2020.
Focused Ultrasound Results in Lasting Benefits for Patients With Essential Tremor
No progressive or delayed complications of treatment were recorded after 3 years in patients with essential tremor who underwent focused ultrasound.
Parkinson Disease Data-Sharing Partnership Launched
The private-public partnership aims to share patient data in hopes of uncovering new biomarkers related to Parkinson disease.
Fenfluramine NDA Accepted for Dravet Syndrome
Fenfluramine is set for priority review by the FDA with a PDUFA date of March 25, 2020.
MS Agent Diroximel Fumarate Associated With Improved GI Tolerability
Results from the phase 3 EVOLVE-MS-2 study demonstrate superior tolerability for now-approved diroximel fumarate compared to dimethyl fumarate.
FDA Gives Go-Ahead to Stem Cell Clinical Trial for Alzheimer Disease
The phase 1/2 trial seeks to will assess the safety and efficacy of mesenchymal stem cells for the treatment of Alzheimer disease.
2 Clarke Drive Cranbury, NJ 08512